The Journal.
Trillion Dollar Shot, Episode 4: The Disruptors
Jun 9, 2024
In this engaging discussion, David Ricks, CEO of Eli Lilly and a pioneer in diabetes and weight-loss medications, delves into the transformative impact of GLP-1 drugs like Ozempic. He highlights the potential for 9% of Americans using these medications by 2030 and discusses the company's skyrocketing revenue from innovative treatments. Ricks also explores how these drugs could revolutionize addiction treatment and disrupt various industries, reshaping health and consumer behavior for years to come.
42:15
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- GLP-1 drugs' popularity may lead to profound ripple effects in industries like healthcare and economy.
- Research is exploring broader health benefits of GLP-1 drugs, from addiction treatment to cardiovascular health.
Deep dives
The Impact of GLP-1 Drugs on Eli Lilly and the Pharma Market
Eli Lilly's success with GLP-1 drugs like terzepatide has disrupted the pharmaceutical industry. These drugs, generating billions in revenue, have caused a shortage due to high demand, leading Lilly to invest in new manufacturing plants. Challenges include supply shortages, retention issues, and varying effectiveness, highlighting the rapid growth of these medications.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
